{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:29:13Z","timestamp":1791289753097,"version":"4.3.0"},"reference-count":94,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T00:00:00Z","timestamp":1204761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral neuropathy (PN) occurs frequently in patients with plasma cell disorders, a heterogeneous group of disorders resulting from the unregulated production of monoclonal proteins. This occurs both due to the dysproteinemia itself and as a consequence of the therapies used to treat the underlying plasma cell disorder. This comprehensive review of PN associated with plasma cell disorders will address both disease and therapy related PN, its pathogenesis and management with particular attention to multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, POEMS syndrome (<jats:italic>polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,<\/jats:italic> and <jats:italic>skin changes)<\/jats:italic> and amyloidosis. An understanding of this topic is critical for health care providers treating patients with plasma cell disorders due to the high frequency with which it occurs, the implications it has on selecting therapies for the underlying disorder and to best guide management of the neuropathy itself. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.845","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T14:46:22Z","timestamp":1204814782000},"page":"55-65","source":"Crossref","is-referenced-by-count":53,"title":["Review of peripheral neuropathy in plasma cell disorders"],"prefix":"10.1002","volume":"26","author":[{"given":"Jeannine","family":"Silberman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1963.00460110102011"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1971.00490050038003"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.35.1.63"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-2065-4_1"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb06033.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(93)90297-C"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2548.2548","article-title":"A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy","volume":"106","author":"Richardson P","year":"2005","journal-title":"Blood"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.11.1480"},{"issue":"2","key":"e_1_2_1_10_2","first-page":"62","article-title":"Paraproteinemia related neuropathies","volume":"92","author":"Nobile\u2010Orazio E","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinemia: comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Yeung KB","year":"1991","journal-title":"J Neurol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.11.7139"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360313"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220614"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.4.710"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2001.tb00407.x"},{"issue":"2","key":"e_1_2_1_17_2","first-page":"CD002827","article-title":"Immunotherapy for IgM anti\u2010myelin associated glycoprotein paraprotein associated neuropathy","author":"Lunn MP","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500463940"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/14786410500441664"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000098996.02934.86"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20386"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240113"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.7.1067"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805283382207"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.2.228"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinemia: comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Yeung KB","year":"1991","journal-title":"J Neurol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300111"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360313"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1212\/WNL.43.7.1304","article-title":"Polyneuropathy associated with monoclonal gammopathy of unknown significance: further evidence that IgM\u2010MGUS neuropathies are different from IgG\u2010MGUS","volume":"43","author":"Suarez GA","year":"1993","journal-title":"Neurology"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252105"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.11.1480"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)30205-6"},{"key":"e_1_2_1_33_2","first-page":"979","article-title":"Neuropathies associated with IgG and IgA monoclonal gammopathy","volume":"158","author":"Nobile\u2010Orazio E","year":"2002","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_1_34_2","first-page":"360","article-title":"Plasma cell disorders: atypical plasma cell syndromes","author":"Dispenzieri A","year":"2005","journal-title":"ASH Education Book"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.2.202"},{"key":"e_1_2_1_36_2","first-page":"611","article-title":"Polyneuropathy in non\u2010secretory osteosclerotic multiple myeloma with immunoglobulin deposition in peripheral nerve tissue","volume":"29","author":"Lavenstein B","year":"1979","journal-title":"Neurology"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood.V87.4.1458.bloodjournal8741458","article-title":"Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome","volume":"87","author":"Gherardi RK","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.2.202"},{"key":"e_1_2_1_39_2","first-page":"1288","volume-title":"Peripheral Neuropathies","author":"Kyle RA","year":"1992"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390824"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703670"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-2046"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.V83.6.1452.1452","article-title":"Waldenstrom's macroglobulinemia","volume":"83","author":"Dimopolous MA","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830450105"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.9.1506"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-055012"},{"key":"e_1_2_1_47_2","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle RA","year":"1995","journal-title":"Semin Hematol"},{"key":"e_1_2_1_48_2","first-page":"665","article-title":"Amyloidosis (AL):clinical and laboratory features in 229 cases","volume":"58","author":"Kyle RA","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/archinte.1989.00390020080016","article-title":"Peripheral neuropathy as an early marker of AL amyloidosis","volume":"149","author":"Duston MA","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00037-0"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2788"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-030544"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070484"},{"key":"e_1_2_1_54_2","first-page":"1287","article-title":"Long term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer","volume":"14","author":"Cavaletti G","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_1_55_2","volume-title":"Management of Complications of Chemotherapy in Gershenson et al.'s Gynaecologic Cancer: Controversies in management","author":"Mileshkin L","year":"2002"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(95)00050-X"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.11.1885"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.21.2.73"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6689"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.53.12.828"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.1109"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00382.x"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.875"},{"key":"e_1_2_1_67_2","first-page":"2505","article-title":"A phase I trial of the novel proteosome inhibitor PS341in advanced solid tumor malignancies","volume":"8","author":"Aghajanian C","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.106"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_1_73_2","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy in the APEX trial","volume":"106","author":"San Miguel JF","year":"2005","journal-title":"Blood"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"issue":"11","key":"e_1_2_1_76_2","first-page":"3547","article-title":"Lenalidomide plus high dose dexamethasone alone for relapsed or refractory multiple myeloma: results of 2 phase 3 studies (MM\u2010009, MM\u2010010) and subgroup analysis of patients with impaired renal function","volume":"108","author":"Weber D","year":"2006","journal-title":"ASH Ann Meet Abstr"},{"issue":"11","key":"e_1_2_1_77_2","first-page":"6","article-title":"Study of lenalidamide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma: results of a phase 3 study (MM\u2010010)","volume":"106","author":"Dimopoulos MA","year":"2006","journal-title":"ASH Ann Meet Abstr"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.21.1831"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.2.251"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.21.1837"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00407-9"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1053\/rapm.2002.35169"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200212000-00046"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2002.11753609"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-4-13"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.11.1524"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.1.89"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1216"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.99.502"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(93)90297-C"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370705"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212313272705"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360313"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199401000-00011"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.2.116"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.845","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:58:57Z","timestamp":1699991937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,6]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1002\/hon.845"],"URL":"https:\/\/doi.org\/10.1002\/hon.845","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,6]]}}}